stoxline Quote Chart Rank Option Currency Glossary
  
Addex Therapeutics Ltd (ADXN)
8.46  -0.018 (-0.21%)    06-20 16:00
Open: 9.78
High: 9.78
Volume: 1,373
  
Pre. Close: 8.478
Low: 8.02
Market Cap: 7(M)
Technical analysis
2025-06-20 4:38:13 PM
Short term     
Mid term     
Targets 6-month :  11.61 1-year :  13.32
Resists First :  9.94 Second :  11.4
Pivot price 8.6
Supports First :  7.57 Second :  6.29
MAs MA(5) :  8.43 MA(20) :  8.5
MA(100) :  7.84 MA(250) :  8.43
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  24.6 D(3) :  20.7
RSI RSI(14): 54.2
52-week High :  13.27 Low :  6.51
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ADXN ] has closed below upper band by 40.7%. Bollinger Bands are 64.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 9.79 - 9.83 9.83 - 9.87
Low: 7.94 - 7.97 7.97 - 8.01
Close: 8.78 - 8.85 8.85 - 8.91
Company Description

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Headline News

Fri, 20 Jun 2025
Trading Resumes for Addex Therapeutics (ADXN) | ADXN Stock News - GuruFocus

Fri, 20 Jun 2025
Addex Therapeutics (ADXN) Trading Halted Due to Volatility | ADXN Stock News - GuruFocus

Fri, 20 Jun 2025
Addex Therapeutics Ltd (ADXN) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial Outlook - GuruFocus

Thu, 19 Jun 2025
Addex Therapeutics Reports Q1 2025 Financial Results - TipRanks

Thu, 19 Jun 2025
Earnings call transcript: Addex Therapeutics highlights Q1 2025 progress - Investing.com

Thu, 19 Jun 2025
Addex Therapeutics Reports Strong Start to 2025 with Key Developments and Financial Gains - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out -3 (M)
Shares Float 0 (M)
Held by Insiders 1.07e+006 (%)
Held by Institutions 3.508e+007 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -444260
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -7.33
Profit Margin 1 %
Operating Margin 720.7 %
Return on Assets (ttm) -29 %
Return on Equity (ttm) 550.7 %
Qtrly Rev. Growth -90.8 %
Gross Profit (p.s.) -40.75
Sales Per Share -83.62
EBITDA (p.s.) -3.01485e+006
Qtrly Earnings Growth -2.56e+006 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value -1.21
Price to Sales -0.11
Price to Cash Flow 0
Stock Dividends
Dividend 2690
Forward Dividend 2020
Dividend Yield 30395.4%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android